Corbus launches DETERMINE, a Phase 3 trial of lenabasum for the treatment of dermatomyositis. Double-blind, randomized, placebo-controlled, efficacy and...
Dermatomyositis (DM) is classified both as a neuromuscular disease and an autoimmune disease. It is thought that the inflammation resulting in cell damage is created when the immune system attacks healthy muscle tissue and blood vessels under the skin. DM can affect both the muscles and the skin.
DM is one of several diseases in the Idiopathic Inflammatory or Acquired Myopathy category. The term “idiopathic” means no known cause, however some cases are known to have been caused by medications, viruses, bacteria, trauma, toxins, cancer or other illness.
- Inclusion Body Myositis Functional Rating Scale (IBMFRS) January 14, 2019
- Inclusion Body Myositis Specialty Clinic at Washington University, St. Louis January 10, 2019
- The first step when approaching a patient with muscle weakness – Differential diagnosis of idiopathic inflammatory myopathies in adults January 9, 2019
January 25 @ 4:00 pm - 5:30 pm EST
February 6 @ 7:00 pm - 8:30 pm EST